



Venetoclax in combination with rituximab

pCODR (Pan-Canadian Oncology Drug Review) Expert Review Committee conditionally recommends reimbursement of venetoclax (Venclexta) in combination with rituximab for the treatment of adult patients with chronic lymphocytic leukemia (CLL) who have received at least one prior therapy, irrespective of their 17p deletion status, only if cost-effectiveness is improved to an acceptable level.

Ontario first province to reimburse venetoclax

Following the signing of an agreement between AbbVie and the pan-Canadian Pharmaceutical Alliance (pCPA), Ontario is the first province to reimburse Venclexta. Venclexta is the first and only BCL-2 inhibitor to be approved in Canada. Venclexta is indicated for the treatment of patients with chronic lymphocytic leukemia (CLL) who have received at least one prior therapy and who have no other treatment options. Venclexta is an oral, once-daily medicine. [Link to Newswire article](#)

What's new regarding frontline combination regimens in CLL

Clinical Care Options shares important new data from recent trials. See the full article here.. . [Link to Clinical Care Options](#)

There have been changes to the CLLPAG Board. As most of you know by now, we lost a most valuable Board member, our first Honourary Board member and founding member of CLLPAG, Chris Dwyer. He served on our Board from 2006 until his death in April of this year.

Lorna Warwick, another long time member of the Board, also left but will continue to offer her valuable advice to the Board if and when requested. Lorna is now the CEO of the Lymphoma Coalition, a global network of worldwide not for profit lymphoma patient organizations.

As a result of these changes there are now vacant Board director positions we would like to fill. If you are a CLL patient or CLL caregiver and are interested please contact Rebecca at: cllpag.canada@gmail.com.